This is an expanded access designed to provide access to Relatlimab for eligible participants.
Drug: Relatlimab
Local Institution
San Francisco, California, 94143
Investigator: Site 0014
Local Institution
Tampa, Florida, 33612
Investigator: Site 0013
Local Institution
Hays, Kansas, 67601
Investigator: Site 0019
The Cancer Center At Hackensack University Medical Center
Hackensack, New Jersey, 07601
Investigator: Michele Donato, Site 0001
Local Institution
Syracuse, New York, 13210
Investigator: Site 0018
Local Institution
Charlottesville, Virginia, 22908
Investigator: Site 0015
Inova Schar Cancer Institute
Fairfax, Virginia, 22031
Investigator: Sekwon Jang, Site 0016
Contact: 571-472-0384
Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,
please email:
Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb